- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07686159
Evaluation of Mosquito Repellent Products' Efficacy, Safety, and Public Health Implications
July 2, 2026 updated by: Ushama Shafoyat, Military Institute of science and Technology
Comparative Evaluation of Mosquito Repellent Products in South Asia and North America: Efficacy, Safety, and Public Health Implications
Human Volunteer Participation:
A total of six (6) healthy adult volunteers participated in the study, including three males and three females aged between 18 and 22 years. The volunteers participated in:
- Arm-in-Cage Test Procedure
- Dermatological Safety Test
All participants were:
- Non-tobacco users
- Free from dermatosis or chronic skin disease
- Free from known allergic reactions to arthropod bites or mosquito repellents
- Informed regarding the objectives, procedures, risks, and benefits of the study Written informed consent was obtained from all volunteers before participation. Participants were instructed not to apply perfumes, aromatics, skincare products, or other mosquito repellents on the hands for at least 12 hours before and during the experiment to minimize experimental bias.
Safety and Ethical Considerations:
- All experiments were conducted under controlled laboratory conditions.
- Appropriate safety precautions and monitoring procedures were maintained throughout the study.
- Volunteers retained the right to withdraw from the study at any stage without penalty.
- Confidentiality and anonymity of volunteer information were strictly maintained.
- No severe physical or psychological risk was associated with participation.
- Immediate medical support and first-aid facilities were available during experimentation.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
6
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Dhaka Division
-
Dhaka, Dhaka Division, Bangladesh, 1216
- Biomedical Engineering Department, Military Institute of Science and Technology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- healthy adult volunteers participated
Exclusion Criteria:
- Sick and children
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Arm-in-Cage Test Procedure
This arm evaluates the efficacy of commercially available skin-applied mosquito repellent formulations against Aedes albopictus females using a standardized WHO-recommended Arm-in-Cage Test (ACT).
The study assesses mosquito landing/biting protection under controlled laboratory conditions using human volunteers and standardized exposure procedures.
|
Specialized rubber gloves designed to expose only a 4 × 4 cm area of dorsal hand skin while protecting the rest of the hand.
Gloves were replaced between trials to prevent cross-contamination or residual repellent effects.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Mosquito Landings on the Treated Forearm During the WHO Arm-in-Cage Test
Time Frame: Measured at 0, 1, 2, 4, 6, and 8 hours after repellent application.
|
The number of mosquito landings on the treated forearm will be counted during each exposure period using the standardized WHO Arm-in-Cage Test with 50 unfed female Aedes aegypti mosquitoes.
|
Measured at 0, 1, 2, 4, 6, and 8 hours after repellent application.
|
|
Number of Confirmed Mosquito Bites During the WHO Arm-in-Cage Test
Time Frame: Measured at 0, 1, 2, 4, 6, and 8 hours after repellent application.
|
The number of confirmed mosquito bites occurring on the treated forearm will be recorded during each exposure period.
|
Measured at 0, 1, 2, 4, 6, and 8 hours after repellent application.
|
|
Complete Protection Time Measured by the WHO Arm-in-Cage Test
Time Frame: Up to 8 hours after application.
|
Complete Protection Time is defined as the elapsed time from repellent application until the first confirmed mosquito landing or bite.
|
Up to 8 hours after application.
|
|
Percentage Protection Against Mosquito Landing
Time Frame: Measured at 0, 1, 2, 4, 6, and 8 hours after application
|
Percentage protection will be calculated by comparing the number of mosquito landings on treated skin with the corresponding control observations.
|
Measured at 0, 1, 2, 4, 6, and 8 hours after application
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Treatment-Related Skin Reactions
Time Frame: Within 8 hours after application.
|
The number of participants experiencing erythema, itching, rash, burning sensation, or other treatment-related skin reactions after topical repellent application.
|
Within 8 hours after application.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 25, 2025
Primary Completion (Actual)
October 25, 2025
Study Completion (Actual)
November 5, 2025
Study Registration Dates
First Submitted
June 5, 2026
First Submitted That Met QC Criteria
July 2, 2026
First Posted (Actual)
July 7, 2026
Study Record Updates
Last Update Posted (Actual)
July 7, 2026
Last Update Submitted That Met QC Criteria
July 2, 2026
Last Verified
July 1, 2026
More Information
Terms related to this study
Other Study ID Numbers
- 2025H009
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mosquito Repellent
-
Malaria Consortium, EthiopiaColumbia University; Addis Ababa University; Coalition Against Malaria in EthiopiaCompletedMalaria | Mosquito Repellent | Long Lasting Insecticidal NetsEthiopia
-
Africa Power LimitedMalaria Consortium; ARCTECH INNOVATION LIMITEDRecruitingMalaria | Mosquito-Borne DiseaseUganda
-
National Institute of Allergy and Infectious Diseases...PepTcell Limited (t/a SEEK)CompletedMosquito-Borne Infectious DiseasesUnited States
-
Institut PasteurMinistry of Health of Vanuatu; Vanuatu National HospitalCompletedCOVID-19 | Dengue | Chikungunya | Zika | Ross River | Arbovirus DiseaseVanuatu
-
Menzies School of Health ResearchAga Khan University; University of Melbourne; Curtin University; Jimma University; Universitas Sumatera Utara and other collaboratorsNot yet recruitingMalariaEthiopia, Indonesia, Pakistan, Papua New Guinea
-
GlaxoSmithKlineNot yet recruiting
-
Institut de Recherche pour le DeveloppementRecruiting
-
National Institute of Allergy and Infectious Diseases...CompletedMosquito-Borne DiseaseUnited States
-
University of OxfordNot yet recruiting
-
University of California, San FranciscoNational Institute of Allergy and Infectious Diseases (NIAID); Ministry of... and other collaboratorsNot yet recruiting
Clinical Trials on Mosquito Repellent Products (Topical and Spatial Formulations)
-
Institute of Tropical Medicine, BelgiumInstitut Pasteur; NCHADS - Ministry of Health of CambodiaCompleted
-
ARCTECCompletedMidge BitesUnited Kingdom
-
The Mentor InitiativeLiverpool School of Tropical Medicine; University of Maiduguri; US government; ...CompletedVector Borne Diseases | Malaria | Childhood ALLUnited Kingdom
-
L'OrealCompletedVisible Light Exposure on Healthy Back SkinRomania
-
Cosmetique Active InternationalCompletedHealthy Volunteers | Hyperpigmentation | Skin PigmentationRomania
-
LEO PharmaCompleted
-
LEO PharmaCompleted
-
Stanford UniversityCompletedBacterial, Viral and Other Infectious AgentsUnited States
-
Saint-Joseph UniversityCompleted
-
King Abdulaziz UniversityCompletedDental Caries and Streptococcus Mutans CountSaudi Arabia